A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment. / Subramanian, Vijaya; Bagger, Jonatan I.; Holst, Jens J.; Knop, Filip K.; Vilsbøll, Tina.

In: Frontiers in Physiology, Vol. 13, 911616, 2022.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Subramanian, V, Bagger, JI, Holst, JJ, Knop, FK & Vilsbøll, T 2022, 'A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment', Frontiers in Physiology, vol. 13, 911616. https://doi.org/10.3389/fphys.2022.911616

APA

Subramanian, V., Bagger, J. I., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2022). A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment. Frontiers in Physiology, 13, [911616]. https://doi.org/10.3389/fphys.2022.911616

Vancouver

Subramanian V, Bagger JI, Holst JJ, Knop FK, Vilsbøll T. A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment. Frontiers in Physiology. 2022;13. 911616. https://doi.org/10.3389/fphys.2022.911616

Author

Subramanian, Vijaya ; Bagger, Jonatan I. ; Holst, Jens J. ; Knop, Filip K. ; Vilsbøll, Tina. / A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment. In: Frontiers in Physiology. 2022 ; Vol. 13.

Bibtex

@article{e8395d4c7c9544c5be121efe0e02b0d6,
title = "A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment",
abstract = "Type 2 diabetes (T2D) is a pathophysiology that is characterized by insulin resistance, beta- and alpha-cell dysfunction. Mathematical models of various glucose challenge experiments have been developed to quantify the contribution of insulin and beta-cell dysfunction to the pathophysiology of T2D. There is a need for effective extended models that also capture the impact of alpha-cell dysregulation on T2D. In this paper a delay differential equation-based model is developed to describe the coupled glucose-insulin-glucagon dynamics in the isoglycemic intravenous glucose infusion (IIGI) experiment. As the glucose profile in IIGI is tailored to match that of a corresponding oral glucose tolerance test (OGTT), it provides a perfect method for studying hormone responses that are in the normal physiological domain and without the confounding effect of incretins and other gut mediated factors. The model was fit to IIGI data from individuals with and without T2D. Parameters related to glucagon action, suppression, and secretion as well as measures of insulin sensitivity, and glucose stimulated response were determined simultaneously. Significant impairment in glucose dependent glucagon suppression was observed in patients with T2D (duration of T2D: 8 (6–36) months) relative to weight matched control subjects (CS) without diabetes (k1 (mM)−1: 0.16 ± 0.015 (T2D, n = 7); 0.26 ± 0.047 (CS, n = 7)). Insulin action was significantly lower in patients with T2D (a1 (10 pM min)−1: 0.000084 ± 0.0000075 (T2D); 0.00052 ± 0.00015 (CS)) and the Hill coefficient in the equation for glucose dependent insulin response was found to be significantly different in T2D patients relative to CS (h: 1.4 ± 0.15; 1.9 ± 0.14). Trends in parameters with respect to fasting plasma glucose, HbA1c and 2-h glucose values are also presented. Significantly, a negative linear relationship is observed between the glucagon suppression parameter, k1, and the three markers for diabetes and is thus indicative of the role of glucagon in exacerbating the pathophysiology of diabetes (Spearman Rank Correlation: (n = 12; (−0.79, 0.002), (−0.73,.007), (−0.86,.0003)) respectively).",
keywords = "glucagon action, glucagon secretion, glucagon suppression, hysteresis, insulin secretion, insulin sensitivity, type 2 diabetes",
author = "Vijaya Subramanian and Bagger, {Jonatan I.} and Holst, {Jens J.} and Knop, {Filip K.} and Tina Vilsb{\o}ll",
note = "Publisher Copyright: Copyright {\textcopyright} 2022 Subramanian, Bagger, Holst, Knop and Vilsb{\o}ll.",
year = "2022",
doi = "10.3389/fphys.2022.911616",
language = "English",
volume = "13",
journal = "Frontiers in Physiology",
issn = "1664-042X",
publisher = "Frontiers Media S.A.",

}

RIS

TY - JOUR

T1 - A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment

AU - Subramanian, Vijaya

AU - Bagger, Jonatan I.

AU - Holst, Jens J.

AU - Knop, Filip K.

AU - Vilsbøll, Tina

N1 - Publisher Copyright: Copyright © 2022 Subramanian, Bagger, Holst, Knop and Vilsbøll.

PY - 2022

Y1 - 2022

N2 - Type 2 diabetes (T2D) is a pathophysiology that is characterized by insulin resistance, beta- and alpha-cell dysfunction. Mathematical models of various glucose challenge experiments have been developed to quantify the contribution of insulin and beta-cell dysfunction to the pathophysiology of T2D. There is a need for effective extended models that also capture the impact of alpha-cell dysregulation on T2D. In this paper a delay differential equation-based model is developed to describe the coupled glucose-insulin-glucagon dynamics in the isoglycemic intravenous glucose infusion (IIGI) experiment. As the glucose profile in IIGI is tailored to match that of a corresponding oral glucose tolerance test (OGTT), it provides a perfect method for studying hormone responses that are in the normal physiological domain and without the confounding effect of incretins and other gut mediated factors. The model was fit to IIGI data from individuals with and without T2D. Parameters related to glucagon action, suppression, and secretion as well as measures of insulin sensitivity, and glucose stimulated response were determined simultaneously. Significant impairment in glucose dependent glucagon suppression was observed in patients with T2D (duration of T2D: 8 (6–36) months) relative to weight matched control subjects (CS) without diabetes (k1 (mM)−1: 0.16 ± 0.015 (T2D, n = 7); 0.26 ± 0.047 (CS, n = 7)). Insulin action was significantly lower in patients with T2D (a1 (10 pM min)−1: 0.000084 ± 0.0000075 (T2D); 0.00052 ± 0.00015 (CS)) and the Hill coefficient in the equation for glucose dependent insulin response was found to be significantly different in T2D patients relative to CS (h: 1.4 ± 0.15; 1.9 ± 0.14). Trends in parameters with respect to fasting plasma glucose, HbA1c and 2-h glucose values are also presented. Significantly, a negative linear relationship is observed between the glucagon suppression parameter, k1, and the three markers for diabetes and is thus indicative of the role of glucagon in exacerbating the pathophysiology of diabetes (Spearman Rank Correlation: (n = 12; (−0.79, 0.002), (−0.73,.007), (−0.86,.0003)) respectively).

AB - Type 2 diabetes (T2D) is a pathophysiology that is characterized by insulin resistance, beta- and alpha-cell dysfunction. Mathematical models of various glucose challenge experiments have been developed to quantify the contribution of insulin and beta-cell dysfunction to the pathophysiology of T2D. There is a need for effective extended models that also capture the impact of alpha-cell dysregulation on T2D. In this paper a delay differential equation-based model is developed to describe the coupled glucose-insulin-glucagon dynamics in the isoglycemic intravenous glucose infusion (IIGI) experiment. As the glucose profile in IIGI is tailored to match that of a corresponding oral glucose tolerance test (OGTT), it provides a perfect method for studying hormone responses that are in the normal physiological domain and without the confounding effect of incretins and other gut mediated factors. The model was fit to IIGI data from individuals with and without T2D. Parameters related to glucagon action, suppression, and secretion as well as measures of insulin sensitivity, and glucose stimulated response were determined simultaneously. Significant impairment in glucose dependent glucagon suppression was observed in patients with T2D (duration of T2D: 8 (6–36) months) relative to weight matched control subjects (CS) without diabetes (k1 (mM)−1: 0.16 ± 0.015 (T2D, n = 7); 0.26 ± 0.047 (CS, n = 7)). Insulin action was significantly lower in patients with T2D (a1 (10 pM min)−1: 0.000084 ± 0.0000075 (T2D); 0.00052 ± 0.00015 (CS)) and the Hill coefficient in the equation for glucose dependent insulin response was found to be significantly different in T2D patients relative to CS (h: 1.4 ± 0.15; 1.9 ± 0.14). Trends in parameters with respect to fasting plasma glucose, HbA1c and 2-h glucose values are also presented. Significantly, a negative linear relationship is observed between the glucagon suppression parameter, k1, and the three markers for diabetes and is thus indicative of the role of glucagon in exacerbating the pathophysiology of diabetes (Spearman Rank Correlation: (n = 12; (−0.79, 0.002), (−0.73,.007), (−0.86,.0003)) respectively).

KW - glucagon action

KW - glucagon secretion

KW - glucagon suppression

KW - hysteresis

KW - insulin secretion

KW - insulin sensitivity

KW - type 2 diabetes

U2 - 10.3389/fphys.2022.911616

DO - 10.3389/fphys.2022.911616

M3 - Journal article

C2 - 36148302

AN - SCOPUS:85138367405

VL - 13

JO - Frontiers in Physiology

JF - Frontiers in Physiology

SN - 1664-042X

M1 - 911616

ER -

ID: 321278762